Brief: Calithera Receives FDA Fast Track Designation For Sapanisertib

Calithera Biosciences

03/10/2022 12:16

Oct 3 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA RECEIVES FDA FAST TRACK DESIGNATION FOR
SAPANISERTIB
FOR THE TREATMENT OF NRF2-MUTATED SQUAMOUS LUNG CANCER

Source text for Eikon:  ID:nGNX6SnLwz 
Further company coverage:  CALA.O 
 ((Reuters.Briefs@thomsonreuters.com;))